1. Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis
- Author
-
Hong-Bae Kim, Jung-Ha Kim, and Bethany J. Wolf
- Subjects
medicine.medical_specialty ,Sociodemographic Factors ,Coronavirus disease 2019 (COVID-19) ,medicine.drug_class ,Proton-pump inhibitor ,Review ,Proton pump inhibitor ,Severity of Illness Index ,Helicobacter Infections ,Sex Factors ,Risk Factors ,Observational study ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Retrospective Studies ,Pharmacology ,Helicobacter pylori ,SARS-CoV-2 ,business.industry ,Incidence ,Incidence (epidemiology) ,Hazard ratio ,H2 receptor antagonists ,Age Factors ,COVID-19 ,Proton Pump Inhibitors ,Retrospective cohort study ,General Medicine ,Confidence interval ,COVID-19 Drug Treatment ,Meta-analysis ,Histamine H2 Antagonists ,Regression Analysis ,business - Abstract
Purpose Several observational studies have presented conflicting results on the association between the use of proton pump inhibitors (PPIs) or histamine H2 receptor antagonist (H2RA) and the risk of coronavirus disease 2019 (COVID-19). This systematic review and meta-analysis aimed to examine this association. Methods In July 2021, PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched for articles investigating the relationship between the two main acid suppressants and COVID-19. Studies showing the effect estimates as hazard ratio (HR) for severe outcomes or incidence of COVID-19 were evaluated using a random-effects model. Results A total of 15 retrospective cohort studies with 18,109 COVID-19 cases were included in the current meta-analysis. PPI use was significantly associated with severe outcomes of COVID-19 (hazard ratio [HR] = 1.53; 95% confidence interval [CI]: 1.20–1.95) but not with the incidence of COVID-19, whereas H2RA use was significantly associated with decreased incidence (HR = 0.86, 95% CI: 0.76–0.97). For subgroup analyses of PPIs, increased severe outcomes of COVID-19 were observed in 60 years, while in-hospital use and use in Asia were associated with higher disease severity. Conclusions Close observation can be considered for COVID-19 patients who use PPIs to prevent severe outcomes. However, caution should be taken because of substantial heterogeneity and plausible protopathic bias. Supplementary information The online version contains supplementary material available at 10.1007/s00228-021-03255-1.
- Published
- 2021